Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
401-420 of 1,782 trials

Memory Disorders: Evaluating Tau PET Imaging

We are studying whether tau PET can improve diagnosis for patients with memory problems. This trial compares its effectiveness to more common and affordable diagnostic tools.

Mild Cognitive Impairment and Dementia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurology

Follicular Lymphoma: Mosunetuzumab and Lenalidomide Study

We are evaluating a new combination treatment for people with untreated follicular lymphoma to see if it works better than standard chemotherapy. This study aims to improve patient outcomes and quality of life.

Follicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Chronic Lymphocytic Leukemia: Venetoclax and Acalabrutinib Treatment

We are studying a combination of venetoclax and acalabrutinib for patients with CLL who have relapsed after previous treatment. The goal is to see if this combination can help achieve better disease control and improve quality of life.

Chronic Lymphocytic LeukemiaPatients with Relapsed CLL>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Erosive Esophagitis: NEXIUM for Kids

We are studying whether NEXIUM can help maintain healing in children aged 1 to 11 with erosive esophagitis. This trial also looks at how well the medication works and any symptoms during treatment.

Erosive Esophagitis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Bacterial Brain Abscess: Oral vs. IV Antibiotics

We are studying whether oral antibiotics are as effective as IV antibiotics for treating bacterial brain abscesses. This trial will help us understand the best treatment options and their impact on recovery and quality of life.

Brain Abscess>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNeurology

Small Bowel Adenocarcinoma: FOLFIRINOX vs. FOLFOX

We are studying two chemotherapy treatments for patients with locally advanced or metastatic small bowel adenocarcinoma. The goal is to find out which treatment helps patients live longer without their cancer worsening.

Small Bowel Adenocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Sparsentan for Pediatric Kidney Diseases

We are studying a new oral treatment for children with certain kidney diseases to see if it is safe and effective. The trial will also evaluate how well children tolerate the medication and its impact on kidney function.

Proteinuric Glomerular Diseases>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Acyclovir for ICU Patients with Herpes Simplex Virus Reactivation

We are studying whether acyclovir can help reduce mortality and improve recovery in intubated patients with Herpes simplex virus reactivation. This trial compares acyclovir to a placebo to see which treatment is more effective.

Herpes Simplex Reactivation>2 yearsConfirmation phase (III)Standard MedicinesInfectious DiseasesInternal Medicine

Giant Cell Arteritis: Stopping Tocilizumab

We are comparing immediate versus gradual stopping of tocilizumab in patients with giant cell arteritis. The goal is to see which method helps prevent relapses and improves quality of life.

Giant Cell Arteritis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesRheumatology

Long-term Safety Study for Ciltacabtagene Autoleucel

We are following up with patients who received cilta-cel to learn about any long-term side effects and how well the treatment works over time. This study aims to improve our understanding of the treatment's safety and effectiveness.

Multiple Myeloma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Ceftazidime-Avibactam for Critically Ill Patients

We are studying the best dosing of ceftazidime-avibactam for critically ill patients on continuous renal replacement therapy. This research aims to improve treatment effectiveness and safety.

Ceftazidime-avibactam Therapy1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNephrology

Hereditary Ichthyosis: Injectable Gentamicin Study

We are studying whether injectable gentamicin can improve skin scaling and redness in people with hereditary ichthyosis. This trial aims to assess its effects on skin condition and overall quality of life.

Congenital Ichthyosis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesDermatology

Refractory Heart Failure: Dapagliflozin Study

We are investigating how Dapagliflozin may help patients with refractory heart failure eliminate sodium and manage fluid levels during peritoneal dialysis. This study aims to improve treatment options for these patients.

Refractory Heart Failure≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineNephrology

Immune Thrombocytopenia: Avatrombopag vs. Rituximab

We are comparing the effectiveness of Avatrombopag and Rituximab in adults with ITP who did not respond to corticosteroids. The study aims to see which treatment better improves health-related quality of life and reduces fatigue.

Immune Thrombocytopenia1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal Medicine

Chronic Migraine in Adolescents: Rimegepant Study

We are investigating whether rimegepant can help prevent migraines in adolescents aged 12 to under 18 with chronic migraine. The study will also assess its safety and how it affects the use of other migraine treatments.

Chronic Migraine1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Posaconazole for Young Children with Fungal Infections

We are studying how well Posaconazole works and its safety in children under 2 years old with invasive fungal infections. This research will help us understand its effects compared to older patients.

Fungal Infection3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPediatrics

Richter's Syndrome: M-CHOP with Mosunetuzumab

We are studying a new treatment combining mosunetuzumab with CHOP for patients with Richter's Syndrome who have not had therapy before. The aim is to evaluate its effectiveness and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

B-Cell Non-Hodgkin’s Lymphoma: Glofitamab and Obinutuzumab Study

We are studying the safety and effectiveness of Glofitamab alone and with Obinutuzumab in patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. This trial aims to find the best dose and understand how these treatments work together.

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Atypical Hemolytic Uremic Syndrome: Crovalimab for Kids

We are studying the safety and effectiveness of crovalimab in children with atypical hemolytic uremic syndrome. This trial includes both new patients and those switching from other treatments.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyNephrology

Non-Small-Cell Lung Cancer: Amivantamab Treatment Study

We are studying the effects of a new antibody treatment, amivantamab, alone and with chemotherapy for patients with early-stage lung cancer. This research aims to see if it helps before surgery and how it affects tumor characteristics.

Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology